ImmunityBio (IBRX) Ownership - Who owns ImmunityBio?

Key Takeaways

• ImmunityBio, Inc. (IBRX) is a U.S.-based clinical- and commercial-stage biotechnology company focused on next-generation immunotherapies for cancer and infectious diseases.
• The company was founded in 2014 and is headquartered in San Diego, California, with its shares listed on the Nasdaq Global Select Market.
• Its lead commercial product is ANKTIVA, an FDA-approved immunotherapy used with BCG to treat a form of non-muscle invasive bladder cancer.
• ImmunityBio pursues a "vertically integrated" model, spanning discovery, manufacturing, and commercialization across multiple immunotherapy platforms.
• As a development-stage biotech, the company has generated growing product revenue but remains unprofitable while funding extensive research and development.

Introduction

ImmunityBio, Inc. (IBRX) is a biotechnology company that develops and commercializes immunotherapies designed to activate the body's own immune system to fight cancer and infectious diseases. Unlike many peers that focus on a single technology, ImmunityBio has built a diversified platform spanning antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Investors follow the stock for its potential to expand its approved therapy into additional indications and markets, while weighing the risks common to clinical-stage biotech companies.

Main Profile

ImmunityBio was founded in 2014 by Patrick Soon-Shiong, a physician and entrepreneur known for his work in life sciences and immunotherapy, and is headquartered in San Diego, California. The company was formerly known as NantCell before adopting the ImmunityBio name. Its shares trade on the Nasdaq Global Select Market under the ticker symbol IBRX.

The company describes itself as a vertically integrated biotechnology firm, meaning it aims to control multiple stages of the drug development process in-house, from research and manufacturing to clinical testing and commercialization. Its scientific approach focuses on activating both the innate immune system (including natural killer, or NK, cells, dendritic cells, and macrophages) and the adaptive immune system (B cells and T cells) to create durable, coordinated immune responses.

ImmunityBio's product platforms include:

• Antibody-cytokine fusion proteins, which combine an immune-signaling molecule with a targeting antibody;
• Vaccine vectors based on DNA, RNA, and adenovirus technologies; and
• Cell therapies, including NK-cell-based approaches.

The company's lead commercial product is ANKTIVA (nogapendekin alfa inbakicept), an IL-15 superagonist antibody-cytokine fusion protein. IL-15 is a naturally occurring signaling protein that helps stimulate and sustain immune cells. ANKTIVA received approval from the U.S. Food and Drug Administration (FDA) for use in combination with Bacillus Calmette-Guérin (BCG) to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. Bladder cancer patients in this setting have limited treatment options after BCG therapy stops working, making ANKTIVA a meaningful addition to the treatment landscape.

In terms of its business model, ImmunityBio generates revenue primarily from product sales of ANKTIVA in the United States, supplemented by collaboration and licensing agreements with organizations such as the National Cancer Institute, Serum Institute of India, and other partners. Because the company continues to invest heavily in clinical trials and platform development, its financial profile reflects substantial research and development spending that has kept the company unprofitable on a net income basis even as revenue has grown.

Why Investors Follow IBRX

ImmunityBio attracts attention because of its differentiated approach to immunotherapy and its potential to expand into multiple oncology and infectious-disease markets. Rather than relying on a single drug, the company's platform strategy aims to generate multiple product candidates that could be tested alone or in combination across liquid tumors, solid tumors, and infectious diseases.

A key long-term growth driver is the opportunity to broaden ANKTIVA's approved indications beyond bladder cancer and into additional tumor types and geographic markets. The company has also reported pursuing regulatory submissions in regions outside the United States, which could expand its addressable market. Its vertically integrated structure is intended to give it greater control over manufacturing and cost, a potential competitive advantage as therapies scale.

The company's leadership, including founder Patrick Soon-Shiong and CEO Richard Adcock, and its partnerships with established research and industry organizations, are additional factors that investors weigh when assessing the company's strategic positioning in the competitive oncology sector.

Risks and Important Considerations

Investing in ImmunityBio carries risks typical of development-stage biotechnology companies. The company's commercial portfolio currently centers on a single approved product, ANKTIVA, which creates concentration risk: a setback in regulatory review, commercialization, or clinical development could have an outsized impact on the business.

The company operates in a highly competitive oncology market alongside large pharmaceutical firms and other biotechs developing immunotherapies. Regulatory approval processes are lengthy and uncertain, and clinical trials may fail to meet their endpoints. Manufacturing biologics at scale is complex, and any quality or supply disruption could affect product availability.

Financially, ImmunityBio has reported ongoing net losses and relies on funding to support its research and development programs, which raises questions about its long-term capital needs. Macroeconomic factors, including interest rates and investor sentiment toward unprofitable biotech companies, can also influence its valuation and access to capital. These factors make IBRX a higher-risk, higher-uncertainty investment relative to more established healthcare companies.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Whether you are researching companies like ImmunityBio or exploring broader themes, the AI Screener offers a structured way to refine your watchlist.

Conclusion

ImmunityBio stands out as a vertically integrated immunotherapy company with an FDA-approved product and a broad platform aimed at cancers and infectious diseases. Its differentiated scientific approach and expansion potential make it a notable name in the biotech sector, while its concentration on a single commercial product and ongoing losses underscore the risks involved. For investors, IBRX represents a case study in the high-reward, high-uncertainty profile characteristic of clinical- and commercial-stage biotechnology.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations